Product news

Share this article:

Novartis' Tekturna HCT (aliskiren and hydrochlorothiazide) has been approved by the FDA as a single-tablet combination of two high blood pressure medicines designed to work together to lower blood pressure. Tekturna is a first in class renin inhibitor approved in the US in 2007 for treatment of hypertension. HCT, sometimes called a “water pill,” is one of the most commonly used high blood pressure medicines.

ZymoGenetics said the FDA has approved Recothrom thrombin, topical (recombinant), the first and only recombinant, plasma-free thrombin approved for use as a topical hemostat. Recothrom is indicated as an aid to hemostasis whenever oozing blood and minor bleeding from capillaries and small venules is accessible and control of bleeding by standard surgical techniques is ineffective or impractical.

Taro Pharmaceutical Industries said its US affiliate, Taro Pharmaceuticals USA, has received FDA approval for its NDA for Flo-Pred (prednisolone acetate oral suspension).The Flo-Pred brand, for which there are no generic equivalents, will be sold by prescription as an anti-inflammatory agent for the treatment of asthma, certain allergic and dermatologic conditions, as well as a variety of other indications. The market for prednisolone oral liquid products was estimated at $55 million in 2007. The Company plans to launch the product later this year and market it through its TaroPharma Division of Taro USA.

Daiichi Sankyo said the FDA has approved Welchol (colesevelam HCl) indicated to improve glycemic control (measured as hemoglobin A1C) in adults with type 2 diabetes mellitus in combination with metformin, sulfonylureas or insulin, either alone or in combination with other anti-diabetic agents. Welchol is the first and only medication approved to reduce both glucose levels and low density lipoprotein cholesterol levels (LDL-C).

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.